Novel Human Indoleamine 2,3-dioxygenase Inhibitors Form A Long-lived Complex With The Enzyme | 63587
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

6th International Conference on Vaccines and Immunology

Geneva, Switzerland

3rd European Congress on Virology

Geneva, Switzerland
Google scholar citation report
Citations : 1600

Journal of Biotechnology & Biomaterials received 1600 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Novel human indoleamine 2,3-dioxygenase inhibitors form a long-lived complex with the enzyme

Joint Event on 15th World Congress on Biotechnology And Biotech Industries Meet and 2nd International Conference on Enzymology and Molecular Biology

Julie Alexandre, Michael Swan, Mike Latchem, Dean Boyall, John Pollard, Stuart Hughes and James Westcott

Vertex Pharmaceuticals Ltd., UK

Posters & Accepted Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.071

Human indoleamine 2,3-dioxygenase 1 (IDO) catalyzes the conversion of L-tryptophan (L-Trp) to N-formylkynurenine through a heme and O2-dependent oxidation process. IDO is recognized as a central regulator of immune responses in a broad variety of physiological and pathological settings and is thus considered an attractive therapeutic target. In search of novel IDO inhibitors, we identified 4-amino-1,2,3-triazoles. Using crystallographic, biochemical and spectroscopic techniques we have fully characterized a representative molecule of this molecular series (VIDOi1) and shown that: VIDOi1 is non-competitive for D-Trp; VIDOi1 interacts with the IDO heme iron VIDOi1 binds to both the ferric and the ferrous form of the enzyme; VIDOi1establishes a slow complex with the ferrous form of IDO; and the VIDOi1-IDO complex is long-lived. The generation of this tight binding complex between IDO and the 4-amino -1,2,3-triazoles leads to exceptional potencies of this molecule series in a cellular context.

Julie Alexandre is specialized in Kinetics at the Vertex Pharmaceuticals Europe Ltd., (Abingdon, UK). She holds a PhD in Biochemistry from the University of Edinburgh (Scotland, UK) and undertook Post-doctoral Research in Enzymology at the Pierre-and-Marie-Curie University (Paris, France). She has been working at Vertex since 9 years and has contributed in many internal drug discovery efforts in oncology, targeting kinases, proteases and redox enzymes, through characterization of enzymes substrates and inhibitors kinetics and mode of action.

Email: [email protected]